Study aim: Evaluation of the effect of oleoyl ethanamide supplementation on inflammatory parameters and biomarkers of oxidative stress in MS patients Design: A total of 50 patients were randomly divided into two groups receiving oleoyl ethanamide supplement and placebo by simple random sampling method. Clinical trial with control group, with parallel groups, three-way blind, randomized Settings and conduct: Fifty patients referred to Shahid Beheshti Hospital in Hamadan (consecutively) who have MS at the diagnosis of a physician, were randomly divided into two groups with respect to allocation (Allocation Concealment). Blinding all organs so that patients are known only by computer code. The treatment codes will be revealed at the end of the study, and it is unclear whether a placebo or supplement will be given, as the placebo capsules will look exactly like oleoyl ethanlamide. Written consent is obtained from patients to participate in the study and participate in sampling. After the intervention, blood is taken from these patients and examined. Participants/Inclusion and exclusion criteria: Inclusion criteria: Willingness to cooperate Recurrent-restricted MS patient Exclusion conditions: Immunosuppressive drugs History of rheumatic and collagen and vascular diseases History of recent infections (during the last 2 to 3 months) Swallowing disorders who are unable to take drugs Sensitivity To non-regular use compounds complement the unwillingness to cooperate Intervention groups: The intervention group should receive 2 oleoyl ethanamide supplements (250 mg) daily with main meals for 6 weeks. The control group should also take 2 placebo capsules daily for 6 weeks. Main outcome variables: Inflammatory parameters and biomarkers of oxidative stress